These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

960 related items for PubMed ID: 22887810

  • 1. BRAF mutation detection in indeterminate thyroid cytology specimens: underlying cytologic, molecular, and pathologic characteristics of papillary thyroid carcinoma.
    Ohori NP, Singhal R, Nikiforova MN, Yip L, Schoedel KE, Coyne C, McCoy KL, LeBeau SO, Hodak SP, Carty SE, Nikiforov YE.
    Cancer Cytopathol; 2013 Apr; 121(4):197-205. PubMed ID: 22887810
    [Abstract] [Full Text] [Related]

  • 2. The prediction of malignant risk in the category "atypia of undetermined significance/follicular lesion of undetermined significance" of the Bethesda System for Reporting Thyroid Cytopathology using subcategorization and BRAF mutation results.
    Hyeon J, Ahn S, Shin JH, Oh YL.
    Cancer Cytopathol; 2014 May; 122(5):368-76. PubMed ID: 24591408
    [Abstract] [Full Text] [Related]

  • 3. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
    Rossi ED, Martini M, Bizzarro T, Capodimonti S, Cenci T, Lombardi CP, Pontecorvi A, Fadda G, Larocca LM.
    Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
    [Abstract] [Full Text] [Related]

  • 4. BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma.
    Rossi ED, Martini M, Capodimonti S, Lombardi CP, Pontecorvi A, Vellone VG, Zannoni GF, Larocca LM, Fadda G.
    Cancer Cytopathol; 2013 Jun; 121(6):291-7. PubMed ID: 23192956
    [Abstract] [Full Text] [Related]

  • 5. Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations.
    Bellevicine C, Sgariglia R, Migliatico I, Vigliar E, D'Anna M, Nacchio MA, Serra N, Malapelle U, Bongiovanni M, Troncone G.
    Cancer Cytopathol; 2018 May; 126(5):317-325. PubMed ID: 29469940
    [Abstract] [Full Text] [Related]

  • 6. Morphological parameters able to predict BRAF(V600E) -mutated malignancies on thyroid fine-needle aspiration cytology: Our institutional experience.
    Rossi ED, Bizzarro T, Martini M, Capodimonti S, Fadda G, Larocca LM, Schmitt F.
    Cancer Cytopathol; 2014 Dec; 122(12):883-91. PubMed ID: 25156883
    [Abstract] [Full Text] [Related]

  • 7. BRAF mutation testing of thyroid fine-needle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance.
    Adeniran AJ, Hui P, Chhieng DC, Prasad ML, Schofield K, Theoharis C.
    Acta Cytol; 2011 Dec; 55(6):570-5. PubMed ID: 22156468
    [Abstract] [Full Text] [Related]

  • 8. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area.
    Chung KW, Yang SK, Lee GK, Kim EY, Kwon S, Lee SH, Park DJ, Lee HS, Cho BY, Lee ES, Kim SW.
    Clin Endocrinol (Oxf); 2006 Nov; 65(5):660-6. PubMed ID: 17054470
    [Abstract] [Full Text] [Related]

  • 9. Significance of Subcategory Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Showing Both Cytologic and Architectural Atypia in Thyroid Aspiration Cytology.
    Jung YY, Jung S, Lee HW, Oh YL.
    Acta Cytol; 2015 Nov; 59(5):370-6. PubMed ID: 26529329
    [Abstract] [Full Text] [Related]

  • 10. Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas.
    Erickson LA, Jin L, Nakamura N, Bridges AG, Markovic SN, Lloyd RV.
    Cancer; 2007 May 15; 109(10):1965-71. PubMed ID: 17387744
    [Abstract] [Full Text] [Related]

  • 11. Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics.
    Radkay LA, Chiosea SI, Seethala RR, Hodak SP, LeBeau SO, Yip L, McCoy KL, Carty SE, Schoedel KE, Nikiforova MN, Nikiforov YE, Ohori NP.
    Cancer Cytopathol; 2014 Dec 15; 122(12):873-82. PubMed ID: 25132659
    [Abstract] [Full Text] [Related]

  • 12. Detection of BRAF V600E mutation in thyroid fine-needle aspiration specimens by High Resolution Melting (HRM) analysis.
    Nechifor-Boilă A, Decaussin-Petrucci M, Gazzo S, Paşcanu I, Borda A.
    Rom J Morphol Embryol; 2012 Dec 15; 53(2):263-7. PubMed ID: 22732794
    [Abstract] [Full Text] [Related]

  • 13. Reduction of false-negative papillary thyroid carcinomas by the routine analysis of BRAF(T1799A) mutation on fine-needle aspiration biopsy specimens: a prospective study of 814 thyroid FNAB patients.
    Cañadas-Garre M, Becerra-Massare P, López de la Torre-Casares M, Villar-del Moral J, Céspedes-Mas S, Vílchez-Joya R, Muros-de Fuentes T, García-Calvente C, Piédrola-Maroto G, López-Nevot MA, Montes-Ramírez R, Llamas-Elvira JM.
    Ann Surg; 2012 May 15; 255(5):986-92. PubMed ID: 22504197
    [Abstract] [Full Text] [Related]

  • 14. [BRAF V600E mutation in papillary thyroid carcinoma: prevalence and detection in fine needle aspiration specimens].
    Dujardin F, Pagès JC, Collin C, de Calan L, Lecomte P, Guyétant S.
    Ann Pathol; 2010 Aug 15; 30(4):252-62. PubMed ID: 20837233
    [Abstract] [Full Text] [Related]

  • 15. False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma.
    Paek SH, Kim BS, Kang KH, Kim HS.
    World J Surg Oncol; 2017 Nov 13; 15(1):202. PubMed ID: 29132392
    [Abstract] [Full Text] [Related]

  • 16. PD-L1 and thyroid cytology: A possible diagnostic and prognostic marker.
    Dell'Aquila M, Granitto A, Martini M, Capodimonti S, Cocomazzi A, Musarra T, Fiorentino V, Pontecorvi A, Lombardi CP, Fadda G, Pantanowitz L, Larocca LM, Rossi ED.
    Cancer Cytopathol; 2020 Mar 13; 128(3):177-189. PubMed ID: 31821747
    [Abstract] [Full Text] [Related]

  • 17. Pilot of BRAF mutation analysis in indeterminate, suspicious and malignant thyroid FNA cytology.
    Johnson SJ, Hardy SA, Roberts C, Bourn D, Mallick U, Perros P.
    Cytopathology; 2014 Jun 13; 25(3):146-54. PubMed ID: 24417615
    [Abstract] [Full Text] [Related]

  • 18. Reflex BRAF testing in thyroid fine-needle aspiration biopsy with equivocal and positive interpretation: a prospective study.
    Adeniran AJ, Theoharis C, Hui P, Prasad ML, Hammers L, Carling T, Udelsman R, Chhieng DC.
    Thyroid; 2011 Jul 13; 21(7):717-23. PubMed ID: 21568726
    [Abstract] [Full Text] [Related]

  • 19. The utility of the Bethesda category and its association with BRAF mutation in the prediction of papillary thyroid cancer stage.
    Beiša A, Kvietkauskas M, Beiša V, Stoškus M, Ostanevičiūtė E, Jasiūnas E, Griškevičius L, Strupas K.
    Langenbecks Arch Surg; 2017 Mar 13; 402(2):227-234. PubMed ID: 28160058
    [Abstract] [Full Text] [Related]

  • 20. A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates.
    Marchetti I, Lessi F, Mazzanti CM, Bertacca G, Elisei R, Coscio GD, Pinchera A, Bevilacqua G.
    Thyroid; 2009 Aug 13; 19(8):837-42. PubMed ID: 19534623
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.